PAVmed (PAVM)
(Delayed Data from NSDQ)
$1.02 USD
-0.03 (-2.40%)
Updated Jul 26, 2024 03:47 PM ET
After-Market: $1.01 -0.01 (-0.49%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
Price, Consensus and EPS Surprise
PAVM 1.02 -0.03(-2.40%)
Will PAVM be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PAVM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PAVM
Why PAVmed Inc. (PAVM) Dipped More Than Broader Market Today
New Strong Buy Stocks for March 27th
PAVM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why PAVmed Inc. (PAVM) Is a Great 'Buy the Bottom' Stock Now
PAVmed Inc. (PAVM) Upgraded to Buy: Here's Why
PAVmed Inc. (PAVM) Upgraded to Strong Buy: Here's What You Should Know
Other News for PAVM
Lucid Diagnostics Announces Record Quarterly EsoGuard? Test Volume
Lucid Diagnostics announces record quarterly EsoGuard test volume
Lucid Diagnostics Launches New Corporate Website
Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard? Esophageal Precancer Testing in a Screening Population
12 Health Care Stocks Moving In Monday's After-Market Session